ArticleScientific reports2026
Retrospective evaluation of high-dose-rate brachytherapy multicriteria planning using physical dose versus radiobiological criteria for prostate cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Radiobiological indices can provide insights into treatment efficacy beyond traditional physical dose metrics and potentially facilitate the comparison between various radiotherapy plans. This study investigates the integration of radiobiological indices with standard physical dose criteria to improve high-dose-rate (HDR) brachytherapy plan evaluation and selection process for the treatment of prostate cancers in a multicriteria optimization (MCO) framework. This is accomplished within the framework of a graphics processing unit-based multicriteria optimization algorithm, gMCO. 2000 Pareto-optimal plans for 200 patients were optimized for a 15 Gy HDR brachytherapy boost after external beam radiation therapy (44 Gy in 22 fractions). Tumour control probability (TCP), normal tissue complication probability (NTCP), and uncomplicated tumour control probability (UTCP) were calculated for each plan. Maximizing UTCP alone resulted in insufficient target coverage (target [Formula: see text]) according to clinical guidelines. Conversely, maximizing target coverage while meeting institutional criteria compromised UTCP significantly (reduction of about 0.09). Selecting plans that met all institutional criteria first, then maximizing UTCP, achieved a balanced compromise between tumour control and normal tissue safety. While combining UTCP and standard dose metrics based on dose-volume histogram (i.e., absorbed dose or physical dose constraints) with MCO can enhance brachytherapy plan optimization, exclusive reliance on standard TCP and NTCP models, using recommended parameters, yields clinically unacceptable plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.